To be held in conjunction with Obesity 2012

Goal
To update healthcare professionals on recent developments in the management of patients with obesity, discuss the biologic mechanisms of new anti-obesity medications, and stratify patient risk to optimize treatment selection.

Learning Objectives
After participating in this activity, participants should be better able to:
  • Characterize the population of patients who are overweight and obese, with specific attention to the relationship between overweight/obesity and comorbid conditions
  • Design management strategies for patients who are overweight and obese
  • Describe risk:benefits of weight-loss medications in treating overweight, obesity, and comorbid conditions
 

Target Audience
Physicians and other healthcare professionals
who treat obesity


Saturday, September 22, 2012
Grand Hyatt San Antonio
Lone Star Ballroom – Salon A/B
600 East Market Street
San Antonio, Texas

Registration and Dinner: 7:00
PM – 7:30 PM
Scientific Program: 7:30 PM – 9:00 PM


Register Now


 
FACULTY
  Course Director and Program Chair
Caroline M. Apovian, MD
Associate Professor of Medicine
and Pediatrics
Boston University School of Medicine
Director, Nutrition and Weight
Management Center
Director, Clinical Research
Obesity Research Center
Boston Medical Center
Boston, Massachusetts

Donna H. Ryan, MD
Professor Emeritus
Pennington Biomedical
Research Center
Baton Rouge, Louisiana

 

Harold E. Bays, MD
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC)
Louisville, Kentucky


  Program Description
This program was developed to educate physicians and other healthcare professionals about recent advances in the treatment of obesity. Historically, few pharmacologic options have been available or of lasting value—although most overweight/obese patients require intervention in addition to behavioral modification to achieve and maintain weight loss. Recently, 2 new options in medical therapy have become available that are effective, possess a good safety profile, and may be used in a broad range of patients, including those with weight-related comorbidities.
   
This activity will present data from clinical trials in new pharmacotherapies, examine the biologic mechanisms of new anti-obesity medications, and discuss risk stratification schemes that can guide clinicians in tailoring weight loss programs for individual patients.

Scientific Program
  • The Pathobiology of Weight Regulation
  • Behavioral Approaches to Weight Loss
  • New Developments in Weight Loss Management
  • Panel Discussion: Risk Stratification in
    Overweight/Obese Patients

Jointly Sponsored By:

Boston UniversityThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Continuing Education Alliance. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
  
Boston University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

   

  
  
Boston University School of Medicine complies with the Americans With Disabilities Act. If any participant is in need of reasonable accommodations, please FAX a written request to 203.487.0406 for consideration at least 2 weeks prior to the activity.
    
This program is supported by an educational grant from Eisai Inc.
   
© 2012 Continuing Education Alliance   CEM79512